Comparing Outpatient and Inpatient Care for Intra-arterial Treatment of Primary Liver Cancer Including Hepato Cellular Carcinoma and Intrahepatic Cholangiocarcinoma

What this Trial Is About

Researchers are comparing two ways of organizing care for patients with primary liver cancer, specifically Hepato Cellular Carcinoma HCC or intrahepatic cholangiocarcinoma iCCA. The study looks at outpatient ambulatory care versus conventional inpatient care for patients receiving transarterial chemoembolization TACE or transarterial radioembolization TARE. The goal is to assess patient satisfaction, safety, and clinical outcomes over a follow-up period of 7 months. The study also includes an evaluation of how well outpatient care can be adopted, its economic impact, and its potential for long-term use. Participants receive either outpatient management with systematic telephone and nursing follow-up for 48 to 72 hours after treatment depending on the procedure, or conventional inpatient hospitalization for their radiological liver cancer treatment. A special re-hospitalization process is available for outpatient participants if complications occur. The study is randomized and multicenter, comparing these two care pathways side by side. During the study, participants will be closely monitored through visits and follow-ups that include assessments of pain, comfort, quality of life, clinical complications, and treatment success. Researchers will also collect data on patient expectations, satisfaction factors, costs, and budget impact over several years. The main outcome is overall patient satisfaction measured 72 hours after the treatment procedure. Participation lasts through the treatment and includes follow-up visits up to 7 months after treatment.

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)